“Steven brings a unique 360-degree perspective on global drug development gained from a career at major pharma companies, CROs and the FDA,” saysAdam Steensberg, Chief Executive Officer, Zealand Pharma. “He joins Zealand at a key moment as we embark on the collaboration with Roche to co-develop and co-commercialize petrelintide as a foundational therapy for people with overweight and obesity. Together, Utpal, Steven and David form a robust, seamless leadership team across research, development and medical affairs as we strive to become a leader in the management of obesity and related complications.”

Steven Johnson

Steven brings nearly 30 years of experience driving drug development and regulatory strategy across the pharmaceutical industry. He joins Zealand Pharma from UCB Biopharma, where he most recently served as Senior Vice President and Head of Regulatory Stakeholders, responsible for leading late phase clinical development, global regulatory affairs, biometrics and operational excellence. During Steven’s tenure at UCB, his teams secured global approvals for key therapies across multiple therapeutic areas. Previously he had senior leadership roles at Medpace, Inc. and at Novo Nordisk. Steven began his career at the U.S. Food and Drug Administration, where he served as a Master Reviewer in the Division of Metabolic and Endocrine Drug Products.

“Zealand Pharma is committed to delivering transformative therapies that are created with the patient’s experience in mind to support long-term health outcomes. I’m excited to work alongside this exceptional team aligning human centered innovation with world class science to develop new therapies that could redefine the standard of care for obesity and more,” says Steven Johnson.

Steven was a Geriatrics Fellow at Washington State University and holds a PharmD, a BPharm, and a BS in Biology, also from Washington State University.